ClinicalTrials.gg
Not yet recruitingNCT07687212Updated Jul 7, 2026

Randomized Double-blind Controlled Clinical Study of SGLT-2i Combined With Probiotic Preparations in Elderly Patients With HFpEF

A Phase 1/2 interventional study of Henggliflozin Combined with Probiotics and Henggliflozin in Heart Failure, Preserved Ejection Fraction, sponsored by The First Affiliated Hospital of Air Force Medicial University. Not yet recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by The First Affiliated Hospital of Air Force Medicial University · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

HFpEF has a high incidence and lacks effective therapy, and its onset is closely related to systemic inflammation and intestinal dysbacteriosis.SGLT-2i exerts its effects by diuresis, anti-inflammatory and improving energy metabolism, whereas probiotics modulate intestinal flora, reduce inflammatory markers, and regulate immune responses.The combination of the two drugs is not only expected to exert synergistic therapeutic potential, but may also reduce the risk of sarcopenia associated with SGLT-2i weight loss.This study aims to combine henagliflozin and a probiotic preparation on the basis of standard anti-heart-failure therapy, and to observe their effects on cardiac and renal function, intestinal barrier function, quality of life, and exercise tolerance in elderly patients with HFpEF, while exploring the underlying mechanisms, so as to provide new data and therapeutic strategies for the treatment of elderly HFpEF patients.

02

Conditions studied

  • Heart Failure, Preserved Ejection Fraction

Keywords

  • heart failure with preserved ejection fraction,HFpEF
  • Henggliflozin
  • Probiotics
03

In context

Heart Failure, Diastolic

199 studies on the registry are indexed under Heart Failure, Diastolic; 44 are open to participants now.

This study's planned enrollment of 162 is above the median of 48 across 139 interventional studies indexed under Heart Failure, Diastolic.

Browse Heart Failure, Diastolic studies →

Lead sponsor

The First Affiliated Hospital of Air Force Medicial University is the lead sponsor of 6 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Age over 60 years; 2.Relevant investigations within 6 months meet diagnostic criteria for HFpEF:

    1. epidemiologic and population characteristics of patients with HFpEF;
    2. presence of symptoms and/or signs of heart failure;
    3. Cardiac imaging suggests >=50%;
    4. BNP>=35pg/ml and (or) NT-pro BNP>=125pg/ml in sinus rhythm, and BNP>=105pg/ml and (or) NT-pro BNP>=365pg/ml in atrial fibrillation;
    5. at least one of the following conditions is met: 1) LVMI>=115 g/m\^2(male)or 95 g/m\^2(female); 2) LAVI>34 ml/m\^2; 3) Relative wall thickness>0.42;or left ventricular free wall thickness>12mm; 4) E/e'>=14; 5) Ventricular septal e'\<7cm/s, or lateral wall e'\<10cm/s, or mean e'\<8cm/s; 6) Tricuspid regurgitant velocity>2.8m/s, or pulmonary artery systolic pressure>35mmHg; 3. class II to III for cardiac function; 4. not taking SGLT-2 inhibitors within 6 months before enrollment; 5. no probiotic preparations taken within 3 months before enrollment; 6. The current anti-HF Therapeutic Regimen is well tolerated by patients and is stable for at least 1 month; 7. Currently stable HF with no acute exacerbations; 8. Cognitive Functioning is basically normal with comprehensible assessment scale content; 9. possess basic behavioral ability, being able to perform daily activities independently or with the help of accessory aids; 10. Understand the purpose of the Clinical Study, voluntarily participate and sign .

Exclusion criteria

Exclusion Criteria:

  • 1. the patient's symptoms are due to noncardiac disease; 2. In those with to Henggliflozin:

    1. those who are allergic to henggliflozin;
    2. severe renal impairment (\<30ml/min/1.73m\^2), end-stage renal disease, or those requiring dialysis; 3. In those with contraindications to probiotics:

    <!-- -->

    1. Patients with severe impairment of the intestinal barrier associated with sepsis, active massive bleeding from the digestive tract, perforation, and other causes.
    2. those with current diagnosis of fulminant colitis or toxic megacolon.
    3. Enteral feeding that cannot tolerate 50% caloric requirement due to severe diarrhea, significant fibrous intestinal stenosis, severe gastrointestinal bleeding, high-flow intestinal fistula, etc.
    4. Patients with congenital or acquired immune deficiency.
    5. Those recently treated with high-risk or cytotoxic drugs: e.g., continued use of rituximab, doxorubicin, or a medium-to high-dose hormone (20 mg/d prednisone or higher) for more than 4 weeks.
    6. Severe immunosuppression: Neutrophils \<1 500/mm\^3. 4. had a myocardial infarction within 6 months before enrollment, had a coronary artery bypass graft procedure, or had any event that could reduce (unless an LVEF >=50%) confirmed; 5. valve replacement surgery within 6 months before enrollment; 6.Poor blood pressure control (SBP>=180mmHg or DBP>=100 mmHg); 7. Current acute decompensated heart failure requires treatment; 8. Resting heart rate exceeding 120 beats/min, or complicated by malignant Arrhythmia; 9. Significant coronary artery lesions require PCI revascularization; 10. Severe renal insufficiency (blood creatinine, Cr >442μmol/L) or receiving dialysis treatment; 11. Patients with urinary tract infection at entry; symptoms and signs of urinary tract infection, such as urinary tract irritation signs (frequent urination, painful urination, urgency), pain and tenderness above the pubic bone, fever, pain or percussion pain in the waist, etc., and urine bacterial culture colony counts >=105/ml; 12. currently having a that requires treatment; 13. Current concurrent acute disease or acute exacerbation of chronic disease; 14.Participated in other interventional investigators within 3 months.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
162 participants (estimated)

Study arms

  • Experimental
    Henggliflozin Combined with Probiotics Group

    Drug: Henggliflozin Combined with Probiotics

  • Experimental
    Henggliflozin Monotherapy Group

    Drug: Henggliflozin

  • Placebo comparator
    double placebo group

    Drug: double placebo

Interventions

  • DrugHenggliflozin Combined with Probiotics

    Primary anti-HF therapy + Henagliflozin Proline Tablets (10mg, 1 times/day) + clostridial enterococcus triple live tablet (400mg, 3 times/day) orally, for 12 weeks.

  • DrugHenagliflozinStudies of HenagliflozinHenagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Primary anti-HF therapy + Henagliflozin Proline Tablets (10mg, 1 times/day) + placebo (400mg, 3 times/day) orally, for 12 weeks.

  • Drugdouble placebo

    Primary anti-HF therapy +Two types of placebo tablets orally, for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Kansas City Cardiomyopathy Questionnaire (KCCQ)scale score

    The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a validated patient-reported outcome measure used to assess heart failure-specific quality of life. The change in the overall summary score from baseline to Week 12 will be compared between the groups. Higher scores indicate better health status.

    Time frame: Baseline, Week 4, Week 8,Week 12

Secondary outcomes

  1. NYHA functional classification

    The New York Heart Association (NYHA) functional classification is used to assess the severity of heart failure symptoms. Changes in NYHA class from baseline to Week 12 will be compared between groups.

    Time frame: Baseline, Week 4, Week 8,Week 12

  2. 6-Minute Walk Test (6MWT) Distance

    The 6-minute walk test is a measure of functional capacity in patients with heart failure. The distance walked in 6 minutes will be assessed at baseline, Week 4, Week 8,and Week 12 to evaluate changes in exercise tolerance.

    Time frame: Baseline, Week 4, Week 8, Week 12

  3. Serum N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) Level

    Serum NT-proBNP is a key biomarker for heart failure severity. Levels will be measured at baseline, Week 4, Week 8, and Week 12 to assess changes in cardiac strain.

    Time frame: Baseline, Week 4, Week 8,Week 12

  4. Minnesota Living with Heart Failure Questionnaire (MLHFQ) Total Score

    The MLHFQ is a patient-reported questionnaire evaluating the impact of heart failure on quality of life. Higher scores indicate greater impairment. Changes from baseline to Week 12 will be compared.

    Time frame: Baseline, Week 4, Week 8,Week 12

  5. Serum Inflammatory Biomarkers (NLRP3, IL-1β, TNF-α, IL-6, MCP-1, ICAM-1, VCAM-1)

    Serum levels of the following inflammatory and endothelial activation markers will be measured to assess the effect of drugs on systemic inflammation in patients with HFpEF: NLRP3, IL-1β, TNF-α, IL-6, MCP-1, ICAM-1, and VCAM-1. Each biomarker will be analyzed separately for changes from baseline.

    Time frame: Baseline, Week 4, Week 8, Week 12

  6. Gut Microbiota Composition and Diversity

    Fecal samples will be collected for 16S rRNA sequencing to analyze changes in gut microbiota composition, diversity, and taxonomic profiles following drugs intervention.

    Time frame: Baseline, Week 4, Week 8, Week 12

  7. Frailty Status Using the Fried Frailty Phenotype Criteria

    Frailty status will be assessed using the Fried criteria to evaluate changes in physical vulnerability.

    Time frame: Baseline, Week 4, Week 8, Week 12

  8. Nutritional Status Using the Mini Nutritional Assessment (MNA) Scale

    Nutritional status will be evaluated using the Mini Nutritional Assessment (MNA) scale. Changes in total score from baseline to Week 12 will be compared.

    Time frame: Baseline, Week 4, Week 8, Week 12

  9. Basic Activities of Daily Living (BADL) Scale Score

    The BADL scale will be used to assess changes in patients' functional independence in daily activities.

    Time frame: Baseline, Week 4, Week 8, Week 12

  10. SARC-F Scale Score

    The SARC-F questionnaire is a validated tool for sarcopenia screening, assessing strength, assistance with walking, rising from a chair, climbing stairs, and falls. Changes in total score from baseline to Week 12 will be evaluated.

    Time frame: Baseline, Week 4, Week 8, Week 12

  11. Fecal Short Chain Fatty Acids (SCFAs)

    Concentrations of fecal short-chain fatty acids, including acetate, propionate, and butyrate, will be quantified to assess changes in gut microbial fermentation.

    Time frame: Baseline, Week 12

  12. Serum Trimethylamine-N Oxide (TMAO)

    Serum TMAO levels will be measured as a marker of gut microbiota-dependent metabolism of dietary phosphatidylcholine and carnitine.

    Time frame: Baseline, Week 12

  13. Serum Bile Acids Profile

    Concentrations of primary and secondary bile acids, such as cholic acid and deoxycholic acid, will be quantified to evaluate changes in bile acid metabolism.

    Time frame: Baseline, Week 12

  14. White Blood Cell (WBC) Count

    WBC count will be measured to monitor changes in systemic inflammatory/immune status.

    Time frame: Baseline, Week 12

  15. Hemoglobin (HGB) Concentration

    Hemoglobin concentration will be measured to assess changes in oxygen-carrying capacity.

    Time frame: Baseline, Week 12

  16. Platelet (PLT) Count

    Platelet count will be measured to evaluate changes in hemostatic/thrombotic potential.

    Time frame: Baseline, Week 12

  17. Serum Creatinine

    Serum creatinine level will be measured to assess renal function.

    Time frame: Baseline, Week 12

  18. Estimated Glomerular Filtration Rate (eGFR)

    eGFR will be calculated as a marker of renal function.

    Time frame: Baseline, Week 12

  19. Alanine Aminotransferase (ALT)

    Serum ALT level will be measured to assess hepatocellular integrity.

    Time frame: Baseline, Week 12

  20. Aspartate Aminotransferase (AST)

    Serum AST level will be measured to assess hepatocellular integrity.

    Time frame: Baseline, Week 12

  21. Fasting Blood Glucose

    Fasting blood glucose concentration will be measured to assess glycemic status.

    Time frame: Baseline, Week 12

  22. Serum Electrolytes (Sodium, Potassium, Chloride)

    Serum concentrations of sodium, potassium, and chloride will be measured. Each electrolyte will be analyzed separately for changes from baseline.

    Time frame: Baseline, Week 12

  23. Left Atrial Volume Index (LAVI)

    LAVI will be measured to assess changes in left atrial remodeling.

    Time frame: Baseline, Week 12

  24. Left Ventricular Mass Index (LVMI)

    LVMI will be measured to assess changes in left ventricular hypertrophy.

    Time frame: Baseline, Week 12

  25. Pulmonary Artery Systolic Pressure (PASP)

    PASP will be measured to assess changes in pulmonary artery pressure.

    Time frame: Baseline, Week 12

  26. E/e' Ratio

    The E/e' ratio will be measured to assess changes in left ventricular filling pressure.

    Time frame: Baseline, Week 12

  27. Total Body Fat Mass

    Body fat mass will be measured to assess changes in adiposity.

    Time frame: Baseline, Week 12

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Sep 2027, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2026
First posted
Jul 7, 2026
StartEst.
Jul 2026
Primary completionEst.
Sep 2027
CompletionEst.
Nov 2027
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07687212
Lead sponsor
The First Affiliated Hospital of Air Force Medicial University
Responsible party
Ji Chenyang (postgraduate student, The First Affiliated Hospital of Air Force Medicial University) — Principal investigator
First posted
Jul 7, 2026
Start date
Jul 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jul 7, 2026

Study contacts

JiChenyang
Contact
3260126173@qq.com
+86 15591423352

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Henagliflozin

Start the discussion